A Phase 2 interventional study of Pertuzumab and Trastuzumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 82 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-28.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.
Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 28th largest by enrollment, is one of 3 that started in 2012, is one of 59 in phase 2, and was the 12th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Wen-Ming Cao · Sites in China
Ages 60+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Alliance for Clinical Trials in Oncology · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pertuzumab is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 63 · Phase 3 23 · Phase 4 3
First in 2003; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 258 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 104 interventional studies. Of the 50 that completed or were terminated, 34 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 104 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 58th largest by enrollment of the 170 interventional ones that give a count, is one of 13 that started in 2012, is one of 65 in phase 2, and was the 90th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
10 of the studies testing pertuzumab in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07187752Shandong Cancer Hospital and InstituteIdentification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes | 2026-12-31 |
| NCT04733118MedSIRChemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 104 studies testing pertuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This randomized, open-label, two-arm, multi-center, Phase II study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab plus an aromatase inhibitor (AI) in first-line participants with HER2-positive and hormone receptor-positive advanced breast cancer. Participants will be randomized to one of two treatment arms; Arm A (pertuzumab in combination with trastuzumab plus an AI) or Arm B (trastuzumab plus an AI). Participants may also receive induction chemotherapy (a taxane, either docetaxel or paclitaxel) at the investigator's discretion in combination with the assigned treatment arm. The anticipated time on study treatment is until disease progression, unacceptable toxicity, withdrawal of consent, or death whichever occurs first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive pertuzumab in combination with trastuzumab plus aromatase inhibitor (AI) until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first. Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion.
Drug: Pertuzumab · Drug: Trastuzumab · Drug: Aromatase Inhibitor · Drug: Induction Chemotherapy
Participants will receive trastuzumab plus aromatase inhibitor (AI) until predefined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first. Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion.
Drug: Trastuzumab · Drug: Aromatase Inhibitor · Drug: Induction Chemotherapy
Participants will receive a loading dose of 840 milligrams (mg) as an intravenous infusion on Day 1 of first treatment cycle, followed by 420 mg on Day 1 or Day 2 of each subsequent 3-week cycle until disease progression or unacceptable toxicity.
Also known as: Perjeta®, rhuMAb 2C4
Participants will receive a loading dose of 8 milligrams per kilogram (mg/kg) as an intravenous infusion on Day 1 or 2 of first treatment cycle, followed by 6 mg/kg on Day 1 or Day 2 of each subsequent treatment 3-week cycles until disease progression or unacceptable toxicity.
Also known as: Herceptin®, rhuMAb HER2
Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.
Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.
This study also gives Anastrozole. No intervention listed here names it: that was found by reading the record.
Progression-Free Survival (PFS)
Progression-free survival (PFS) was defined as the time from randomization until the first radiographically documented progression of disease or death from any cause, whichever occurred first (either during study treatment or during follow-up). Progression of disease was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 and is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum of target lesion diameters must also demonstrate an absolute increase of at least 5 mm (Note: the appearance of one or more new lesions is also considered progression). Participants with no PFS events were censored at the time of the last evaluable tumor assessment. The primary analysis of PFS was planned to be performed when a total of 165 PFS events had occurred, and the final analysis after at least 60 months follow-up.
Time frame: Median [full range] of follow-up time on study for: Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B; Final Analysis: 73.20 [0.03-88.34] months vs. 71.06 [0.03-88.97] months in Arm A vs. Arm B
Overall Survival (OS)
Overall survival (OS) was defined as the time from the date of randomization to the date of death, regardless of the cause of death. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication (pertuzumab, trastuzumab, AI or induction chemotherapy), and participants with no post-baseline information were censored at the date of randomization. The primary analysis of OS was planned to be performed at the same time as for PFS (when a total of 165 PFS events had occurred), and the final analysis was planned after at least 60 months follow-up for all participants.
Time frame: Median [full range] of follow-up time on study for: Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B; Final Analysis: 73.20 [0.03-88.34] months vs. 71.06 [0.03-88.97] months in Arm A vs. Arm B
Overall Response Rate (ORR)
The overall response rate (ORR) was defined as the percentage of participants with best (confirmed) overall response (BOR) of either complete response (CR) or partial response (PR) from start of study treatment until progressive disease (PD)/recurrence or death, as assessed by the investigator according to RECIST version 1.1. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference baseline sum diameters; stable disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Participants needed to have two consecutive assessments of PR or CR at least 4 weeks apart to be a responder. Analysis of this outcome measure was only planned to occur at the time of primary analysis.
Time frame: Median [full range] of follow-up time on study for Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B
Clinical Benefit Rate (CBR)
Clinical Benefit Rate (CBR) was defined as the percentage of participants with best (confirmed) partial response (PR) or complete response (CR) or stable disease (SD) for at least 6 months. According to RECIST version 1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Analysis of this outcome measure was only planned to occur at the time of primary analysis.
Time frame: Median [full range] of follow-up time on study for Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B
Duration of Response (DOR)
Duration of response (DOR) was defined as the period from the date of initial confirmed partial response (PR) or complete response (CR) until the date of progressive disease or death from any cause. According to RECIST version 1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants with no documented progression after CR or PR were censored at the last date at which they were known to have had the CR or PR, respectively. The primary analysis of DOR was planned to be performed at the same time as for PFS (when a total of 165 PFS events had occurred), and the final analysis was planned after at least 60 months follow-up for all participants.
Time frame: Median [full range] of follow-up time on study for: Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B; Final Analysis: 73.20 [0.03-88.34] months vs. 71.06 [0.03-88.97] months in Arm A vs. Arm B
Time to Response (TTR)
Time to Response (TTR) was defined as the time from the date of randomization to the date of first complete response (CR) or partial response (PR). According to RECIST version 1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For participants who did not have a confirmed response, a censored TTR was calculated at the date of the last adequate tumor assessment. If no tumor assessment is performed for the participant (or all post-baseline assessments are not evaluable or PD) the censoring day would be set to day 1 (date of randomization). Analysis of this outcome measure was only planned to occur at the time of primary analysis.
Time frame: Median [full range] of follow-up time on study for Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B
Change From Baseline in Health-Related Quality of Life as Determined by European Quality of Life 5-Dimension (EQ-5D) Visual Analog Scale (VAS) Scores
The EQ-5D VAS is a participant-rated questionnaire to assess health-related quality of life (QoL) in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
Time frame: Baseline and every 3 cycles until treatment discontinuation (up to Cycle 120; 1 cycle is 21 days)
Overview of the Number of Participants With Adverse Events, Severity Determined According to NCI-CTCAE Version 4.03
All adverse events (AEs) occurring during the study and until the post-treatment safety follow-up visit approximately 28 days after last study medication were recorded; thereafter, only study drug-related serious adverse events (SAEs) continued to be collected. The investigator graded all AEs for severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. AEs suggestive of congestive heart failure (CHF) were identified by the SMQ (wide) "Cardiac Failure" with a status of "serious", which included the preferred terms cardiac failure, left ventricular dysfunction, and pulmonary oedema.
Time frame: From Baseline until the end of post-treatment follow-up (up to 89 months)
Number of Participants Who Died Over the Course of the Study by Reported Cause of Death and Time of Death Relative to First or Last Dose of Study Treatment
The causes of death over the course of the study, regardless of whether the death was related to study treatment, are listed by preferred term according to the Medical Dictionary for Regulatory Activities (MedDRA), version 22.1.
Time frame: From Baseline until the end of post-treatment follow-up (up to 89 months)
Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Values Over the Course of the Study
Left ventricular ejection fraction (LVEF) is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram or multiple-gated acquisition (MUGA) scan. All participants must have had a baseline LVEF of at least (≥)50% to enroll in the study; patients with clinically significant cardiovascular disease or baseline LVEF below 50% were not eligible for this study.
Time frame: Baseline and every 3 cycles until treatment discontinuation (up to Cycle 120; 1 cycle is 21 days)
| Milestone | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy |
|---|---|---|
| Started | 129 | 129 |
| Received at least one dose of study drug | 127 | 124 |
| Entered follow-up (post-treatment) | 120 | 116 |
| Completed | 0 | 0 |
| Not completed | 129 | 129 |
| Withdrew: Withdrawal by subject | 20 | 17 |
| Withdrew: Lost to follow-up | 2 | 10 |
| Withdrew: Death | 63 | 57 |
| Withdrew: Study termination by sponsor | 36 | 36 |
| Withdrew: Reason not specified | 8 | 9 |
Progression-free survival (PFS) was defined as the time from randomization until the first radiographically documented progression of disease or death from any cause, whichever occurred first (either during study treatment or during follow-up). Progression of disease was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 and is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum of target lesion diameters must also demonstrate an absolute increase of at least 5 mm (Note: the appearance of one or more new lesions is also considered progression). Participants with no PFS events were censored at the time of the last evaluable tumor assessment. The primary analysis of PFS was planned to be performed when a total of 165 PFS events had occurred, and the final analysis after at least 60 months follow-up.
| months | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy |
|---|---|---|
| Primary Analysis | 18.89 (14.09 to 27.66) | 15.80 (11.04 to 18.56) |
| Final Analysis | 20.63 (14.39 to 28.35) | 15.80 (11.04 to 18.66) |
Overall survival (OS) was defined as the time from the date of randomization to the date of death, regardless of the cause of death. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication (pertuzumab, trastuzumab, AI or induction chemotherapy), and participants with no post-baseline information were censored at the date of randomization. The primary analysis of OS was planned to be performed at the same time as for PFS (when a total of 165 PFS events had occurred), and the final analysis was planned after at least 60 months follow-up for all participants.
| Months | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy |
|---|---|---|
| Primary Analysis | NA (NA to NA) | NA (41.40 to NA) |
| Final Analysis | 60.16 (47.21 to 79.01) | 57.17 (45.44 to NA) |
The overall response rate (ORR) was defined as the percentage of participants with best (confirmed) overall response (BOR) of either complete response (CR) or partial response (PR) from start of study treatment until progressive disease (PD)/recurrence or death, as assessed by the investigator according to RECIST version 1.1. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference baseline sum diameters; stable disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Participants needed to have two consecutive assessments of PR or CR at least 4 weeks apart to be a responder. Analysis of this outcome measure was only planned to occur at the time of primary analysis.
| percentage of participants | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy |
|---|---|---|
| ORR (CR + PR) | 63.3 (53.5 to 72.3) | 55.7 (45.7 to 65.3) |
| Non-responders (SD + PD + NE) | 36.7 (27.7 to 46.5) | 44.3 (34.7 to 54.3) |
| Complete Response (CR) | 7.3 (3.2 to 14.0) | 0.9 (0.0 to 5.1) |
| Partial Response (PR) | 56.0 (46.1 to 65.5) | 54.7 (44.8 to 64.4) |
| Stable Disease (SD) | 26.6 (18.6 to 35.9) | 27.4 (19.1 to 36.9) |
| Progressive Disease (PD) | 5.5 (2.0 to 11.6) | 12.3 (6.7 to 20.1) |
| Not Evaluable (NE) | 4.5 (1.5 to 10.4) | 4.7 (1.5 to 10.7) |
Clinical Benefit Rate (CBR) was defined as the percentage of participants with best (confirmed) partial response (PR) or complete response (CR) or stable disease (SD) for at least 6 months. According to RECIST version 1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Analysis of this outcome measure was only planned to occur at the time of primary analysis.
| percentage of participants | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy |
|---|---|---|
| CBR (CR + PR + SD for ≥6 Months) | 68.8 (59.2 to 77.3) | 67.0 (57.2 to 75.8) |
| Complete Response (CR) | 7.3 (3.2 to 14.0) | 0.9 (0.0 to 5.1) |
| Partial Response (PR) | 56.0 (46.1 to 65.5) | 54.7 (44.8 to 64.4) |
| Stable Disease (SD) for ≥6 Months | 5.5 (2.0 to 11.6) | 11.3 (6.0 to 18.9) |
Duration of response (DOR) was defined as the period from the date of initial confirmed partial response (PR) or complete response (CR) until the date of progressive disease or death from any cause. According to RECIST version 1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants with no documented progression after CR or PR were censored at the last date at which they were known to have had the CR or PR, respectively. The primary analysis of DOR was planned to be performed at the same time as for PFS (when a total of 165 PFS events had occurred), and the final analysis was planned after at least 60 months follow-up for all participants.
| months | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy |
|---|---|---|
| Primary Analysis | 27.10 (14.13 to NA) | 15.11 (12.09 to 20.96) |
| Final Analysis | 27.40 (15.24 to 44.35) | 16.36 (12.09 to 20.96) |
Time to Response (TTR) was defined as the time from the date of randomization to the date of first complete response (CR) or partial response (PR). According to RECIST version 1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For participants who did not have a confirmed response, a censored TTR was calculated at the date of the last adequate tumor assessment. If no tumor assessment is performed for the participant (or all post-baseline assessments are not evaluable or PD) the censoring day would be set to day 1 (date of randomization). Analysis of this outcome measure was only planned to occur at the time of primary analysis.
| months | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy |
|---|---|---|
| Time to Response (TTR) | 2.53 (2.10 to 4.37) | 3.91 (2.10 to 4.17) |
The EQ-5D VAS is a participant-rated questionnaire to assess health-related quality of life (QoL) in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
| unit on a scale | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy |
|---|---|---|
| Baseline (BL) - Value at Visit | 73.0 ± 19.34 | 72.8 ± 18.83 |
| Change from BL at Cycle 3 | 3.3 ± 14.90 | 1.9 ± 15.67 |
| Change from BL at Cycle 6 | 3.5 ± 18.91 | 0.5 ± 13.63 |
| Change from BL at Cycle 9 | 5.3 ± 18.80 | 2.1 ± 15.20 |
| Change from BL at Cycle 12 | 10.7 ± 17.91 | 4.0 ± 15.34 |
| Change from BL at Cycle 15 | 9.1 ± 17.25 | 1.4 ± 22.16 |
| Change from BL at Cycle 18 | 7.5 ± 12.85 | 3.5 ± 15.76 |
| Change from BL at Cycle 21 | 5.8 ± 13.68 | 3.5 ± 19.70 |
| Change from BL at Cycle 24 | 6.2 ± 14.30 | 3.2 ± 16.66 |
| Change from BL at Cycle 27 | 7.5 ± 14.01 | 3.9 ± 22.00 |
| Change from BL at Cycle 30 | 8.3 ± 14.25 | 4.9 ± 16.98 |
| Change from BL at Cycle 33 | 5.1 ± 14.70 | 4.3 ± 15.59 |
| Change from BL at Cycle 36 | 7.3 ± 15.19 | 5.9 ± 15.13 |
| Change from BL at Cycle 39 | 8.1 ± 16.33 | 2.4 ± 29.68 |
| Change from BL at Cycle 42 | 6.4 ± 19.18 | 9.0 ± 17.55 |
| Change from BL at Cycle 45 | 9.7 ± 15.01 | 9.9 ± 19.52 |
| Change from BL at Cycle 48 | 8.8 ± 12.50 | 6.8 ± 17.22 |
| Change from BL at Cycle 51 | 7.2 ± 14.81 | 9.1 ± 19.11 |
| Change from BL at Cycle 54 | 4.7 ± 23.48 | 7.6 ± 17.85 |
| Change from BL at Cycle 57 | 6.8 ± 18.08 | 10.5 ± 16.81 |
| Change from BL at Cycle 60 | 8.2 ± 15.88 | 10.9 ± 18.27 |
| Change from BL at Cycle 63 | 4.0 ± 20.88 | 8.8 ± 14.64 |
| Change from BL at Cycle 66 | 10.4 ± 16.92 | 4.1 ± 15.69 |
| Change from BL at Cycle 69 | 7.5 ± 17.35 | 5.0 ± 16.77 |
| Change from BL at Cycle 72 | 6.2 ± 16.10 | 5.8 ± 16.10 |
| Change from BL at Cycle 75 | 8.6 ± 19.12 | 5.1 ± 15.50 |
| Change from BL at Cycle 78 | 12.8 ± 17.45 | 6.9 ± 14.58 |
| Change from BL at Cycle 81 | 11.5 ± 18.39 | 8.0 ± 14.76 |
| Change from BL at Cycle 84 | 11.2 ± 19.71 | 1.3 ± 18.13 |
| Change from BL at Cycle 87 | 11.2 ± 18.17 | -3.0 ± 11.22 |
| Change from BL at Cycle 90 | 10.9 ± 18.28 | -3.0 ± 12.36 |
| Change from BL at Cycle 93 | 7.1 ± 15.43 | 6.6 ± 13.89 |
| Change from BL at Cycle 96 | 7.5 ± 16.04 | 8.6 ± 12.64 |
| Change from BL at Cycle 99 | 4.4 ± 17.22 | 5.6 ± 16.71 |
| Change from BL at Cycle 102 | 5.6 ± 16.35 | 10.0 ± 17.32 |
| Change from BL at Cycle 105 | 4.4 ± 16.35 | 0.0 ± NA |
| Change from BL at Cycle 108 | 4.0 ± 14.39 | 0.0 ± NA |
| Change from BL at Cycle 111 | 3.3 ± 21.50 | — |
| Change from BL at Cycle 114 | -1.3 ± 17.97 | — |
| Change from BL at Cycle 117 | -5.0 ± NA | — |
| Change from BL at Cycle 120 | -5.0 ± NA | — |
All adverse events (AEs) occurring during the study and until the post-treatment safety follow-up visit approximately 28 days after last study medication were recorded; thereafter, only study drug-related serious adverse events (SAEs) continued to be collected. The investigator graded all AEs for severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. AEs suggestive of congestive heart failure (CHF) were identified by the SMQ (wide) "Cardiac Failure" with a status of "serious", which included the preferred terms cardiac failure, left ventricular dysfunction, and pulmonary oedema.
| Participants | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy |
|---|---|---|
| Any Adverse Event (AE) | 122 | 122 |
| Any AE, Grade ≥3 | 72 | 51 |
| Any Serious Adverse Event (SAE), Grade ≥3 | 35 | 22 |
| Any AE, Grade 5 | 1 | 1 |
| Any SAE | 46 | 28 |
| SAE Related to Pertuzumab | 10 | NA |
| SAE Related to Trastuzumab | 9 | 2 |
| SAE Related to Docetaxel | 6 | 4 |
| SAE Related to Paclitaxel | 3 | 0 |
| Any AE Leading to Discontinuation of Any Treatment | 20 | 10 |
| Any AE Leading to Pertuzumab Discontinuation | 16 | NA |
| Any AE Leading to Trastuzumab Discontinuation | 16 | 6 |
| Any AE Leading to Interruption of Any Treatment | 59 | 26 |
| Any AE Leading to Pertuzumab Interruption | 44 | NA |
| Any AE Leading to Trastuzumab Interruption | 48 | 16 |
| Any AE Related to Pertuzumab | 82 | NA |
| Any AE Related to Trastuzumab | 81 | 62 |
| AE Suggestive of Congestive Heart Failure | 5 | 1 |
The causes of death over the course of the study, regardless of whether the death was related to study treatment, are listed by preferred term according to the Medical Dictionary for Regulatory Activities (MedDRA), version 22.1.
| Participants | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy |
|---|---|---|
| Total Number of Deaths | 62 | 57 |
| Deaths Related to Any Study Treatment | 0 | 0 |
| Cause of Death: Cardiac Arrest | 1 | 0 |
| Cause of Death: Craniocerebral Injury | 1 | 0 |
| Cause of Death: Dyspnoea | 1 | 0 |
| Cause of Death: High-grade B-cell Lymphoma | 1 | 0 |
| Cause of Death: Sudden Death | 0 | 1 |
| Cause of Death: Unevaluable Event | 2 | 1 |
| Cause of Death: Progressive Disease | 56 | 55 |
| Total Deaths Within 30 Days After First Dose | 0 | 0 |
| Total Deaths Within 28 Days After Last Dose | 1 | 2 |
| Total Deaths Within 60 Days After Last Dose | 2 | 4 |
Left ventricular ejection fraction (LVEF) is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram or multiple-gated acquisition (MUGA) scan. All participants must have had a baseline LVEF of at least (≥)50% to enroll in the study; patients with clinically significant cardiovascular disease or baseline LVEF below 50% were not eligible for this study.
| Percentage points of LVEF | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy |
|---|---|---|
| Baseline (BL) - Absolute LVEF at Visit | 63.8 ± 6.23 | 63.9 ± 6.12 |
| Change from BL at Cycle 3 | -1.0 ± 6.25 | -1.4 ± 6.23 |
| Change from BL at Cycle 6 | -2.3 ± 6.66 | -1.3 ± 6.03 |
| Change from BL at Cycle 9 | -2.5 ± 6.80 | -2.2 ± 6.52 |
| Change from BL at Cycle 12 | -2.4 ± 8.05 | -2.8 ± 6.99 |
| Change from BL at Cycle 15 | -2.9 ± 8.67 | -2.5 ± 6.94 |
| Change from BL at Cycle 18 | -1.9 ± 6.42 | -1.3 ± 6.19 |
| Change from BL at Cycle 21 | -1.1 ± 6.01 | -1.1 ± 6.64 |
| Change from BL at Cycle 24 | -2.1 ± 6.82 | -0.6 ± 6.19 |
| Change from BL at Cycle 27 | -1.6 ± 5.05 | -1.3 ± 5.87 |
| Change from BL at Cycle 30 | -1.4 ± 5.20 | -0.3 ± 6.03 |
| Change from BL at Cycle 33 | -2.8 ± 5.60 | 1.2 ± 6.71 |
| Change from BL at Cycle 36 | -2.5 ± 5.50 | -0.2 ± 5.41 |
| Change from BL at Cycle 39 | -2.6 ± 5.72 | 1.4 ± 4.87 |
| Change from BL at Cycle 42 | -2.1 ± 5.91 | 1.9 ± 6.12 |
| Change from BL at Cycle 45 | -1.0 ± 5.54 | 3.0 ± 5.27 |
| Change from BL at Cycle 48 | -3.3 ± 6.56 | -0.2 ± 7.50 |
| Change from BL at Cycle 51 | -1.4 ± 5.82 | 1.0 ± 4.19 |
| Change from BL at Cycle 54 | -1.3 ± 6.17 | -1.0 ± 6.23 |
| Change from BL at Cycle 57 | -1.7 ± 6.43 | 0.8 ± 5.68 |
| Change from BL at Cycle 60 | -2.5 ± 5.54 | -0.9 ± 3.91 |
| Change from BL at Cycle 63 | -2.1 ± 6.10 | 0.8 ± 5.99 |
| Change from BL at Cycle 66 | -2.9 ± 7.80 | -0.4 ± 5.17 |
| Change from BL at Cycle 69 | -2.1 ± 7.23 | -1.5 ± 7.68 |
| Change from BL at Cycle 72 | -3.0 ± 4.97 | -1.0 ± 5.75 |
| Change from BL at Cycle 75 | -3.3 ± 6.59 | -1.1 ± 6.97 |
| Change from BL at Cycle 78 | -3.3 ± 5.58 | -1.1 ± 7.82 |
| Change from BL at Cycle 81 | -2.9 ± 6.83 | -2.6 ± 6.00 |
| Change from BL at Cycle 84 | -2.5 ± 7.66 | -4.5 ± 3.59 |
| Change from BL at Cycle 87 | -3.8 ± 5.76 | -1.4 ± 5.12 |
| Change from BL at Cycle 90 | -2.4 ± 7.69 | 0.4 ± 6.77 |
| Change from BL at Cycle 93 | -1.8 ± 6.57 | -3.9 ± 6.00 |
| Change from BL at Cycle 96 | -0.7 ± 7.45 | -3.2 ± 5.50 |
| Change from BL at Cycle 99 | -3.4 ± 5.78 | -2.8 ± 8.41 |
| Change from BL at Cycle 102 | -1.3 ± 6.12 | -1.6 ± 9.68 |
| Change from BL at Cycle 105 | -0.4 ± 7.05 | -2.0 ± 12.17 |
| Change from BL at Cycle 108 | -3.4 ± 5.32 | -3.3 ± 8.33 |
| Change from BL at Cycle 111 | -6.3 ± 5.91 | -5.5 ± NA |
| Change from BL at Cycle 114 | -4.0 ± 5.35 | -1.4 ± NA |
| Change from BL at Cycle 117 | -11.0 ± NA | — |
| Change from BL at Cycle 120 | -11.0 ± NA | — |
Collected over From Baseline until end of post-treatment follow-up (up to 89 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | 63/129 (48.8%) | 46/127 (36.2%) | 120/127 (94.5%) |
| Arm B: Trastuzumab + AI +/- Chemotherapy | 57/129 (44.2%) | 28/124 (22.6%) | 116/124 (93.5%) |
| Event | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy |
|---|---|---|
| PneumoniaInfections and infestations | 6/127 | 1/124 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/127 | 2/124 |
| Left ventricular dysfunctionCardiac disorders | 4/127 | 0/124 |
| HypersensitivityImmune system disorders | 3/127 | 0/124 |
| GastroenteritisInfections and infestations | 3/127 | 0/124 |
| Device related infectionInfections and infestations | 0/127 | 2/124 |
| Atrial fibrillationCardiac disorders | 2/127 | 0/124 |
| DiarrhoeaGastrointestinal disorders | 2/127 | 1/124 |
| VomitingGastrointestinal disorders | 2/127 | 1/124 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/127 | 0/124 |
| Event | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 70/127 | 45/124 |
| NauseaGastrointestinal disorders | 47/127 | 34/124 |
| AlopeciaSkin and subcutaneous tissue disorders | 38/127 | 40/124 |
| AstheniaGeneral disorders | 39/127 | 32/124 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 38/127 | 31/124 |
| Oedema peripheralGeneral disorders | 34/127 | 23/124 |
| VomitingGastrointestinal disorders | 31/127 | 21/124 |
| AnaemiaBlood and lymphatic system disorders | 28/127 | 18/124 |
| FatigueGeneral disorders | 21/127 | 25/124 |
| CoughRespiratory, thoracic and mediastinal disorders | 25/127 | 18/124 |
Intent-to-Treat (ITT) population included all randomized participants.
| Age, Continuous(Years) | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy | Total |
|---|---|---|---|
| Mean | 60.9 ± 10.85 | 62.3 ± 11.54 | 61.6 ± 11.20 |
| Sex: Female, Male(Participants) | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy | Total |
|---|---|---|---|
| Female | 129 | 129 | 258 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 10 | 18 | 28 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 5 | 9 |
| White | 104 | 93 | 197 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 11 | 12 | 23 |
| Race/Ethnicity, Customized(Participants) | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy | Total |
|---|---|---|---|
| Hispanic/Latino | 45 | 40 | 85 |
| Chinese | 0 | 0 | 0 |
| Indian (Indian subcontinent) | 10 | 16 | 26 |
| Japanese | 0 | 1 | 1 |
| Mixed Ethnicity | 0 | 0 | 0 |
| Other | 63 | 60 | 123 |
| Missing | 11 | 12 | 23 |
| Number of Participants by Induction Chemotherapy and Prior Adjuvant Hormone Therapy(Participants) | Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy | Arm B: Trastuzumab + AI +/- Chemotherapy | Total |
|---|---|---|---|
| Induction Chemotherapy - Yes — <12 Months Since Hormone Therapy | 12 | 12 | 24 |
| Induction Chemotherapy - Yes — ≥12 Months Since Hormone Therapy | 24 | 23 | 47 |
| Induction Chemotherapy - Yes — No Prior Hormone Therapy | 39 | 38 | 77 |
| Induction Chemotherapy - No — <12 Months Since Hormone Therapy | 12 | 12 | 24 |
| Induction Chemotherapy - No — ≥12 Months Since Hormone Therapy | 18 | 19 | 37 |
| Induction Chemotherapy - No — No Prior Hormone Therapy | 24 | 25 | 49 |
Ran from Feb 2012 to primary completion in Mar 2016, 49 months.
Results were first posted in Jun 2017, 1 year 2 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 49 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pertuzumab